Valeant Pharma (VRX) Adds to Gains Ahead of Andrew Left Interview

After gaining 4.4% Monday on Citron Research Andrew Left's long disclosure, Valeant Pharma (NYSE: VRX) is on watch today as Mr. Left will be on CNBC's Halftime Report at 12PM ET to discuss the stock.

Mr. Left is notorious for helping gut the stock last year with his 'Valeant is the next Enron' hit piece. Shares are down dramatically since that point on financial restatements, alleged corporate maleficence, regulatory pressure, a changing business model, etc.

Shares are adding 2.4% early.

.@CitronResearch Andrew Left
will join @HalftimeReport exclusively on Tuesday to discuss why he's now long $VRX pic.twitter.com/SbtZD011V6

— CNBC Halftime Report (@HalftimeReport) May 16, 2016

You May Also Be Interested In

• BofA: Equities and bonds witnessed weekly inflows; no landing much more probable
• BofA says there is a continued strength in buybacks
• B. Riley Financial (RILY) touching day low of $27, giving back half the day's gains